Gilteritinib
82 interactions 305 cited referencesGilteritinib is used to treat a certain type of acute myeloid leukemia (AML) that has worsened or returned after treatment with other chemotherapy medications. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be neede… Read the full Gilteritinib drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Gilteritinib Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Gilteritinib Phenytoin Dilantin Reduced gilteritinib exposure Details Gilteritinib Posaconazole Noxafil Increased gilteritinib plasma concentrations Details Gilteritinib Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Gilteritinib Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Gilteritinib Ribociclib Kisqali Increased gilteritinib plasma concentrations Details Gilteritinib Rifampin Rifadin Reduced gilteritinib exposure Details Gilteritinib Ritonavir Norvir Increased gilteritinib plasma concentrations Details Gilteritinib Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Gilteritinib Saquinavir Increased gilteritinib plasma concentrations Details Gilteritinib Sirolimus Felycin Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib St John's Wort Reduced gilteritinib exposure Details Gilteritinib Sunitinib Sutent Increased BCRP substrate exposure and increased incidence and severity of adverse reactions associated with the BCRP substrate Details Gilteritinib Tacrolimus Astagraf Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Gilteritinib Telaprevir Increased gilteritinib plasma concentrations Details Gilteritinib Telithromycin Increased gilteritinib plasma concentrations Details Gilteritinib Tolvaptan Jynarque Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib Vimseltinib Romvimza Increased risk of P-gp substrate exposure Details Gilteritinib Voriconazole Vfend Increased gilteritinib plasma concentrations Details Gilteritinib Ketoconazole Topical Extina® Foam Increased gilteritinib exposure Details Gilteritinib Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Gilteritinib Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Gilteritinib Letermovir Injection Prevymis Increased CYP3A substrate exposure DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist